Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne.
作者信息
Ballanger Fabienne, Auffret Nicole, Leccia Marie-Thérèse, Claudel Jean Paul, Dréno Brigitte
机构信息
Private practice, Talence, France.
Private practice, Paris, France.
出版信息
Acta Derm Venereol. 2023 Jun 22;103:adv11657. doi: 10.2340/actadv.v103.11657.
Abstract
摘要
相似文献
1
Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne.使用 Janus 激酶抑制剂治疗后出现的痤疮样皮损而非痤疮：Janus 激酶相关性痤疮的诊断与管理
Acta Derm Venereol. 2023 Jun 22;103:adv11657. doi: 10.2340/actadv.v103.11657.
2
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study.接受乌帕替尼治疗的中度至重度特应性皮炎患者中JAK抑制剂相关痤疮的临床结局与管理：一项多中心回顾性研究
J Am Acad Dermatol. 2024 May;90(5):1031-1034. doi: 10.1016/j.jaad.2024.01.004. Epub 2024 Jan 9.
3
Management of acne induced by JAK inhibitors.JAK抑制剂所致痤疮的管理
Dermatol Ther. 2022 Sep;35(9):e15688. doi: 10.1111/dth.15688. Epub 2022 Jul 19.
4
Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis.Janus 激酶抑制剂与皮肤科适应证中痤疮不良事件的系统评价和网络荟萃分析。
J Dermatolog Treat. 2024 Dec;35(1):2397477. doi: 10.1080/09546634.2024.2397477. Epub 2024 Sep 1.
5
Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.特应性皮炎患者发生痤疮的风险与使用系统性Janus激酶抑制剂治疗之间的关联：一项系统评价和荟萃分析
Inflamm Res. 2023 Sep;72(9):1861-1871. doi: 10.1007/s00011-023-01789-x. Epub 2023 Sep 14.
6
Vitamin A acid in acneiform dermatoses.维甲酸在痤疮样皮肤病中的应用。
Acta Derm Venereol Suppl (Stockh). 1975;74:119-27.
7
Activation of Janus kinase signaling pathway in acne lesions.痤疮皮损中 Janus 激酶信号通路的激活。
Dermatol Ther. 2021 Jan;34(1):e14563. doi: 10.1111/dth.14563. Epub 2020 Nov 30.
8
Review and Management of Acneiform Eruptions in Patients with Immune Disorders.免疫功能紊乱患者痤疮样皮损的评估与治疗。
Am J Clin Dermatol. 2017 Jun;18(3):333-341. doi: 10.1007/s40257-017-0256-2.
9
Current concepts in acne management.痤疮管理的当前概念。
Adolesc Med Clin. 2006 Oct;17(3):613-37; abstract x-xi. doi: 10.1016/j.admecli.2006.06.014.
10
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.地夸磷索钠滴眼液治疗干眼的随机、双盲、安慰剂对照多中心临床试验
J Dermatol. 2020 Feb;47(2):114-120. doi: 10.1111/1346-8138.15173. Epub 2019 Dec 9.
引用本文的文献
1
Fungal Head and Neck Dermatitis: Current Understanding and Management.真菌性头颈部皮炎：当前的认识和管理。
Clin Rev Allergy Immunol. 2024 Jun;66(3):363-375. doi: 10.1007/s12016-024-09000-7. Epub 2024 Jul 20.
2
Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.特应性皮炎患者发生痤疮的风险与使用系统性Janus激酶抑制剂治疗之间的关联：一项系统评价和荟萃分析
Inflamm Res. 2023 Sep;72(9):1861-1871. doi: 10.1007/s00011-023-01789-x. Epub 2023 Sep 14.
本文引用的文献
1
Recent advances in understanding inflammatory acne: Deciphering the relationship between Cutibacterium acnes and Th17 inflammatory pathway.近年来对炎症性痤疮的认识进展：解析痤疮丙酸杆菌与 Th17 炎症通路的关系。
J Eur Acad Dermatol Venereol. 2023 Mar;37 Suppl 2:3-11. doi: 10.1111/jdv.18794.
2
Management of acne induced by JAK inhibitors.JAK抑制剂所致痤疮的管理
Dermatol Ther. 2022 Sep;35(9):e15688. doi: 10.1111/dth.15688. Epub 2022 Jul 19.
3
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.阿巴西普、巴瑞替尼和乌帕替尼治疗中重度特应性皮炎的疗效和安全性比较：一项网络荟萃分析。
Dermatol Ther. 2022 Sep;35(9):e15636. doi: 10.1111/dth.15636. Epub 2022 Jul 27.
4
Two Phase 3 Trials of Baricitinib for Alopecia Areata.两项关于巴瑞替尼治疗斑秃的3期试验。
N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26.
5
Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib.用于治疗特应性皮炎的 Janus 激酶抑制剂：聚焦阿布昔替尼、巴瑞替尼和乌帕替尼。
Dermatol Pract Concept. 2021 Oct 1;11(4):e2021145. doi: 10.5826/dpc.1104a145. eCollection 2021 Oct.
6
Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.特应性皮炎治疗的创新：新兴的局部和口服 Janus 激酶抑制剂。
Allergol Int. 2022 Jan;71(1):40-46. doi: 10.1016/j.alit.2021.10.004. Epub 2021 Nov 21.
7
Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.Janus激酶（JAK）抑制剂在特应性皮炎短期治疗中的安全性。
Int J Dermatol. 2022 Jun;61(6):746-754. doi: 10.1111/ijd.15853. Epub 2021 Aug 22.
8
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.中重度特应性皮炎系统治疗药物的疗效和安全性比较：系统文献回顾和网络荟萃分析。
J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1797-1810. doi: 10.1111/jdv.17351. Epub 2021 Jun 12.
9
Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib.新兴的系统性JAK抑制剂治疗特应性皮炎：阿布昔替尼、巴瑞替尼和乌帕替尼的综述
Drugs Context. 2020 Nov 16;9. doi: 10.7573/dic.2020-8-5. eCollection 2020.
10
Activation of Janus kinase signaling pathway in acne lesions.痤疮皮损中 Janus 激酶信号通路的激活。
Dermatol Ther. 2021 Jan;34(1):e14563. doi: 10.1111/dth.14563. Epub 2020 Nov 30.
Zotero 插件